Description
Phase
Phase 2 - takes the treatment one step further, assessing the activity of a particular therapy in a disease, often building upon leads from the Phase I trial. While patients are generally required to be previously untreated, participation in a Phase II trial doesn't usually preclude the patient from getting the standard treatment after they've received the investigational agent. At best they are allowed to get a new drug they wouldn't be able to get otherwise that may turn out to be better for their disease.Inclusion and Exclusion Criteria
Please contact Shirley Sian to learn more about the eligibility criteria for this trial. Please use the contact form on the right side.
Sites
-
California
- USC/Kenneth Norris Comprehensive Cancer Center USC 2, Los Angeles, California, 90033
- Cedars Sinai Medical Center TKI258A2211 (SC), Los Angeles, California, 90048
- University of California at Los Angeles UCLA 3, Los Angeles, California, 90095
- St. Jude Heritage Medical Group St Jude, Fullerton, California, 92835
-
Washington
- Cancer Care Northwest SC, Spokane, Washington, 99202
-
Texas
- South Texas Oncology and Hematology, PA South Tex Onc, San Antonio, Texas, 78258
- Texas Oncology, P.A. SC, Fort Worth, Texas, 76104
- Texas Oncology, P.A. Austin, Bedford, Texas, 76022
- Texas Oncology, P.A. Tex Onc (3), Bedford, Texas, 76022
-
Nebraska
- Southeast Nebraska Oncology Cancer Center, Lincoln, Nebraska, 68510
-
Iowa
- University of Iowa Hospitals & Clinics SC, Iowa City, Iowa, 52242
-
Tennessee
- The West Clinic SC, Memphis, Tennessee, 38120
- Community Oncology Research Network, Chattanooga, Tennessee, 37403
-
Alabama
- University of South Alabama / Mitchell Cancer Institute Univ South Alabama, Mobile, Alabama, 36688
-
Indiana
- Indiana University Health Goshen Center for Cancer IU Simon Cancer, Indianapolis, Indiana, 46202
-
PI
- Novartis Investigative Site, Pisa, PI, 56126
-
Spain
- Novartis Investigative Site, Murcia, 30008
Powered by
SC CTSI